Protein interacting with C kinase (PICK1) is a suppressor of spinocerebellar ataxia 3-associated neurodegeneration in Drosophila by McGurk, Leeanne & Bonini, Nancy M.
Protein interacting with C kinase (PICK1)
is a suppressor of spinocerebellar ataxia
3-associated neurodegeneration in Drosophila
Leeanne McGurk1 and Nancy M. Bonini1,2,∗
1Department of Biology, University of Pennsylvania,
2Howard Hughes Medical Institute, Philadelphia, PA 19104, USA
Received May 16, 2011; Revised September 12, 2011; Accepted September 20, 2011
Spinocerebellar ataxia 3 (SCA3) is the most common autosomal dominant ataxia. The disease is caused by an
expansion of a CAG-trinucelotide repeat region within the coding sequence of the ATXN3 gene, and this
results in an expanded polyglutamine (polyQ) tract within the Ataxin-3 protein. The polyQ expansion leads
to neuronal dysfunction and cell death. Here, we tested the ability of a number of proteins that interact
with Ataxin-3 to modulate SCA3 pathogenicity using Drosophila. Of 10 candidates, we found four novel
enhancers and one suppressor. The suppressor, PICK1 (Protein interacting with C kinase 1), is a transport
protein that regulates the trafﬁcking of ion channel subunits involved in calcium homeostasis to and from
the plasma membrane. In line with calcium homeostasis being a potential pathway mis-regulated in SCA3,
we also found that down-regulation of Nach, an acid sensing ion channel, mitigates SCA3 pathogenesis in
ﬂies. Modulation of PICK1 could be targeted in other neurodegenerative diseases, as the toxicity of SCA1
and tau was also suppressed when PICK1 was down-regulated. These ﬁndings indicate that interaction
proteins may deﬁne a rich source of modiﬁer pathways to target in disease situations.
INTRODUCTION
The most common dominantly inherited ataxia is spinocerebel-
lar ataxia 3 (SCA3). The mutation is the result of a CAG-
trinucleotide expansion in the coding region of the ATXN3
gene, which leads to the expression of a large stretch of gluta-
mines (polyQ) within the protein. There are eight other polyQ
diseases, including several of the SCAs (SCA1, 2, 6, 7 and
17) and Huntington’s disease. Although the genes responsible
for the polyQ diseases appear to be different in amino acid
sequence and function, they share pathological hallmarks. For
example, this group of diseases is characterized by the forma-
tion of polyQ protein aggregates in the nucleus or cytoplasm
(1–4). Studies show that the polyQ accumulations sequester
proteins involved in the ubiquitin proteasome system (UPS)
(5–8). In addition to UPS impairment, it has been proposed
that the toxic polyQ protein may impair transcription, mito-
chondrial function, cytoskeletal transport, genome stability
and calcium homeostasis (9). Several therapeutic compounds
havebeenproposedthattargetproteinmis-foldingandaggrega-
tion, excitotoxic mechanisms and oxidative stress (10,11).
It has become apparent that the polyQ proteins can interact
with each other. For example, loss of the Drosophila ATXN2
homologue, dAtx2, mitigates SCA1 and SCA3 pathogenesis,
suggesting the possibility of mis-regulation of common
molecular pathways (12,13). In addition, a human protein–
protein interaction network for 23 different ataxia-causing
proteins and 31 ataxia-interacting proteins (14) revealed an
interconnected protein network that may prove critical to
pathogenesis in humans. Indeed, novel disease interactors
were found in the ataxia network, including Puratrophin-1
(pleckstrin homology domain containing, family G), which
was independently identiﬁed as an interactor of SCA1 (15).
One of the genes in the ataxia-interactome, AFG3L2, was
found to be responsible for SCA28 (16). These ﬁndings high-
light that the effects observed in neurodegenerative diseases
characterized by ataxia may in part be due to disruption of
shared or interacting networks.
The use of model organisms has revealed great insight into
the key genes that mediate polyQ-associated neurodegenera-
tion, particularly Drosophila (8,17). To identify novel and
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that have been shown to interact with and are predicted to be
one to two proteins away from direct interaction with the
Ataxin-3 protein in the ataxia interaction network (14). Our
studies reveal that the network could be used to successfully
predict genetic modiﬁers of pathogenesis. Our data deﬁne
PICK1 (Protein interacting with C Kinase 1) as a modiﬁer
of SCA3 pathogenesis, as well as Ataxin-1 and tau-associated
toxicity. These data suggest that PICK1-associated pathways
may be neuroprotective and a potential target for neurodegen-
erative diseases.
RESULTS
The SCA3–Friedreich’s ataxia network
The ataxia interactome was a project based on 54 proteins, of
which 23 are ataxia-causing genes and 31 are genes that were
interactors of or paralogues of ataxia-causing genes. Yeast
two-hybrid analysis using these 54 genes as bait revealed
561 interacting proteins. Further database mining with the
615 proteins extended the network to 3607 that could be
involved in the pathogenesis of ataxia (14). We concentrated
on the proteins identiﬁed as direct interactors of Ataxin-3.
Of the 10 proteins, 9 have clear sequence orthologues in the
Drosophila genome: Rad23A and Rad23B both share
sequence similarity to Rad23, and Caspase 1 and Caspase 2
share sequence homology with Ice (Fig. 1). We excluded
VCP from our analysis because it is an established modulator
of SCA3 pathogenesis (18).
One proposed mechanism of polyQ toxicity is mitochon-
drial dysfunction (19–21). Oxidative stress has been shown
to cause an increase in the nuclear accumulation of both patho-
genic and normal Ataxin-3 protein, indicating that oxidative
stress may be an important factor that inﬂuences the pathogen-
esis of SCA3 (22). One of the interactors, PICK1, connects
Ataxin-3 with the mitochondrial protein Frataxin, which is re-
sponsible for Friedreich’s ataxia (FA) (23). FA and SCA3
share pathology in that the purkinje cells are preserved,
unlike SCA1 and SCA2, and both SCA3 and FA affect the
dentate nuclei and the dorsal nuclei of Clarke (24). We
therefore included the FA network in the analysis of SCA3
pathogenesis.
The effect of the FA network on SCA3 pathogenesis
To investigate whether the FA network could genetically inter-
act with SCA3 toxicity, we ﬁrst tested the effect of down-
regulating the frataxin homolog (fh) gene. Expression of the
polyQ domain of mutant Ataxin-3 (SCA3trQ78) in all tissues
of the ﬂy eye using the eye-speciﬁc gmr-GAL4 driver results
in degeneration of the external eye (Fig. 2A). To test the
effect of fh, and additional FA-network genes on
SCA3-associated toxicity, we co-expressed SCA3trQ78 with
RNAi lines directed to fh, Aconitase (Acon), CG3731 and
a-actinin (Actn) in the ﬂy eye. We consistently saw an
enhancement with two independent RNAi lines directed to fh,
with RNAi lines directed to Acon (a protein involved in the tri-
carboxylic acid cycle) and with CG3731 (which in mammals
cleaves the leader peptides from proteins transported into the
Figure 1. The SCA3-FA network. The ataxia interactome was used to predict protein interactors of Ataxin-3 in Drosophila (14). Out of the 10 direct interactors
of Ataxin-3, 8 have a clear sequence counterpart in Drosophila. Ataxin-3 is one node away from frataxin, the protein responsible for FA. Due to the histopatho-
logical similarities between these two diseases, we chose to include the FA-network in our analysis.
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expression of the fh and Acon RNAi transgenes with gmr-GAL4
alone had no effect, whereas expression of the CG3731 RNAi
transgene alone produced a very mild disruption of the external
eye (Supplementary Material, Fig. S1). Down-regulation of
Actn, an actin-binding protein, had no effect on SCA3trQ78
degenerative eye phenotype (Fig. 2E). These data suggest that
the down-regulation of components of the mitochondria can
enhance SCA3 pathogenesis.
To determine whether these modiﬁers are dosage-sensitive
regulators, we tested whether up-regulation of components of
the frataxin network could mitigate SCA3trQ78 pathogenesis.
UAS-fh and UAS-Acon were co-expressed with SCA3trQ78.
We found no modiﬁcation of the external or internal retinal
morphology (Supplementary Material, Fig. S2). These data
suggest that although down-regulation of these genes that
inﬂuence mitochondrial function can enhance SCA3 pathogen-
esis, up-regulation of these components does not mitigate
toxicity indicating that other players in this process may be
the dose-sensitive regulators of this interaction.
RNAi knockdown of Ataxin-3 interactors reveals new
regulators of pathogenesis
To identify additional genes involved in the pathogenesis of
SCA3, we concentrated on the proteins that had been identi-
ﬁed to directly interact with the Ataxin-3 protein (14) and
knocked-down the expression of those genes by RNAi. This
revealed that the reduction in RhoGAP68F expression
enhanced the eye phenotype of SCA3trQ78 (Fig. 2F).
RhoGAP68F, the Drosophila counterpart of the human gene
ARHGAP, is a GTPase activating protein that negatively reg-
ulates Rho GTPase (25). No phenotype was observed when the
RhoGAP68F transgene was expressed with gmr-GAL4 alone
(Supplementary Material, Fig. S1).
We identiﬁed one gene, PICK1 (protein interacting with C
kinase 1), that, when knocked-down, suppressed the external
eye degeneration of SCA3trQ78 (Fig. 2G). Real-time poly-
merase chain reaction (PCR) analysis was performed on
ﬂies globally reducing PICK1 with the daughterless-GAL4
(da-GAL4) driver. The da-GAL4 driver is expressed in all
tissues; this allowed us to determine the efﬁciency of the
knock-down without dilution of wild-type gene levels from
tissues not expressing the RNAi transgene. Real-time PCR
showed that the PICK1 RNAi line reduced the PICK1
mRNA level to below 20% of the control (Fig. 3C). The
internal retinal structure of ﬂies co-expressing SCA3trQ78
and the RNAi transgene to PICK1 also revealed mitigated
degeneration (Fig. 3A). Suppression was conﬁrmed with an
independent PICK1 RNAi line, a deﬁciency line
and heterozygous loss of PICK1 (Supplementary Material,
Fig. S3).
To further test the suppression of SCA3trQ78 upon down-
regulation of PICK1, we also examined the loss of photorecep-
tor neuronal integrity with knockdown of PICK1 by RNAi or
heterozygous loss of endogenous PICK1 (26) using an
adult-onset assay directing the pathogenic polyQ protein to
the photoreceptor neurons. Both of these situations signiﬁcant-
ly suppressed the degeneration of photoreceptor neurons
(Fig. 3D), indicating that the reduction in PICK1 is neuropro-
tective in the SCA3trQ78 ﬂy model both with developmental
toxicity and in the adult stages.
Figure 2. SCA3 candidate modiﬁers. (A) Expression of strong SCA3trQ78 causes degeneration of the external ﬂy eye. Genotype: w; gmr-GAL4,
UAS-SCA3trQ78/UAS-mCD8-GFP. (B–E) Genes of the frataxin network. Genotypes: w; gmr-GAL4, UAS-SCA3trQ78 in trans to the alleles indicated. (B–
D) Genes of the frataxin network that enhance the SCA3trQ78 degenerate eye phenotype. (E) Reduction of Actn, a frataxin network protein, has no effect
on the SCA3trQ78 degenerate eye phenotype. (F–J) Genes of the SCA3 network. Genotypes: w; gmr-GAL4, UAS-SCA3trQ78 in trans to the alleles indicated.
(F) RhoGAP68F when knocked-down enhances the SCA3trQ78 degenerate eye phenotype. (G) Reduction in PICK1 suppresses the SCA3trQ78 eye phenotype.
(H–J) Genes of the SCA3 network, when knocked-down, that have no effect on the SCA3trQ78 degenerate eye phenotype.
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insoluble SCA3trQ78 protein accumulation
The formation of polyQ aggregates is a hallmark of the polyQ
diseases. In SCA3, the aggregates form insoluble nuclear
inclusions (NIs). Expression of SCA3trQ78 in differentiated
photoreceptor neurons with the adult-onset photoreceptor
driver, rhodopsin-1-GAL4 (rh1-GAL4), allowed us to
examine degeneration slowly over time in the adult, and is
more sensitive for analysis of changes in protein levels. Ex-
pression of SCA3trQ78 in adult photoreceptor neurons
results in the detection of insoluble SCA3trQ78 by d3
(Fig. 4A). Co-expression of the RNAi transgene to PICK1
or heterozygous loss of endogenous PICK1 reduced the
amount of insoluble SCA3trQ78 and increased the amount
of soluble protein, such that the ratio of soluble protein (pre-
sented as amount of soluble protein relative to tubulin
loading control) was signiﬁcantly increased (Fig. 4B). At d3,
the formation of NIs can be observed in the retina of ﬂies
expressing SCA3trQ78, with the rh1-GAL4 driver (Fig. 4C).
Reduction in PICK1 with the RNAi transgene caused a
change in the appearance of the accumulations, such that
they appeared less compact, and a trend for fewer inclusions
was observed (Fig. 4C–E).
To test the broader role of PICK1 to modulate
neurodegenerative-associated proteins, we then tested the
ability of PICK1 to affect Tau toxicity. Mutation in the
microtubule-binding protein, Tau, leads to the formation of
insoluble, hyperphosphorylated-Tau positive neuroﬁbrillary
tangles in Alzheimer’s disease (27–29). We expressed a
mutant form of human Tau, hTau.R406W, with either the
PICK1 RNAi transgene or with heterozygous loss of endogen-
ous PICK1. These experiments showed that the reduction in
PICK1 suppressed the toxicity of hTau.R406W (Fig. 4F). Het-
erozygous loss of PICK1 did not suppress the Tau.R406W as
well as the RNAi line (Fig. 4E); however, PICK1 in the het-
erozygous condition is anticipated to be  50%, whereas the
RNAi line directed to PICK1 reduced the levels of PICK1 to
20% of the wild-type (Fig. 3C). These data indicate that down-
regulation of PICK1 activity may be protective in a number of
different neurodegenerative situations.
A reduction in Nach expression mitigates SCA3
pathogenicity in ﬂies
PICK1 is known to act as a transport protein that trafﬁcs the
GluR2 subunit away from the plasma membrane and the
acid sensing ion channels (ASICs) to the plasma membrane
Figure 3. Reduction in PICK1 is neuroprotective in SCA3. (A) Expression of SCA3trQ78 causes external and internal degeneration, with pigment loss and
disintegration of retinal structure. Genotype w; gmr-GAL4, UAS-SCA3trQ78/UAS-mCD8-GFP. Black arrow indicates loss of tissue, and double-headed
arrow indicates retinal tissue width. (B) Knockdown of PICK1 gene expression suppresses the degeneration of the SCA3trQ78 external eye and deterioration
of the retinal structure. Genotype w; gmr-GAL4, UAS-SCA3trQ78/UAS-PICK1-IR. The red arrow indicates preservation of retinal tissue, and double-headed
arrow indicates retinal tissue width. (C) Global expression of UAS-PICK1-IR with the daughterless-GAL4 (da-GAL4) driver causes a consistent knock-down
of PICK1 expression compared with the control, mean+SEM is shown, ∗P , 0.001. (D) The suppression of the SCA3trQ78 degenerate eye phenotype is
not due to a reduction in SCA3 transgene expression. One-way analysis of variance (ANOVA) was performed followed by a Tukey’s post-test, ∗P , 0.05,
mean+SEM. (E) Photoreceptor neural degeneration is suppressed by PICK1 reduction. Photoreceptor neurons were counted in eyes of ﬂies by optical neutral-
ization. Representative images of each genotype are shown and the mean+SEM number of ommatidia is indicated below each image. An aged-matched wild-
type control shows the expected non-degenerated ommatidial structure with seven photoreceptors. Data are 10–20 ommatidia of at least 10 ﬂies per genotype,
repeated three independent times. (F) The distribution of ommatidia in female adults at d21. Expression of SCA3trQ78 in the photoreceptor neurons with the
rhodopsin-1-GAL4 (rh1-GAL4) driver results in a severe loss in the number of photoreceptor neurons at day 21. Reduction in PICK1, either by the co-expression
of the UAS-PICK1 RNAi transgene or by heterozygous loss of endogenous PICK1, suppresses the photoreceptor loss at day 21, ∗P , 0.001, mean+SEM.
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inﬂux of calcium ions, and under conditions of traumatic neur-
onal injury and ischemia, this leads to an increase in cell death
(33–37). Interestingly, calcium excitotoxicity has also been
proposed to be involved in the pathogenesis of a number of
neurodegenerative diseases, including SCA3, SCA1 and Hun-
tington’s disease, and suppression of the mammalian ACCN2
gene (an ASIC) suppresses Huntington’s disease-associated
pathology in cells (38–43). These data raised the hypothesis
that a reduction in ion channels, and their associated effects
on excitability, may also suppress SCA3trQ78 toxicity in ﬂies.
PICK1-mediated transport of ion channels involved in gluta-
matergic signaling is dependent upon PKCa (30,31,32). We
found that inhibition of or a reduction in PKCa failed to sup-
press SCA3trQ78 toxicity (Supplementary Material, Fig. S4).
In addition, the main neurotransmitter in the ﬂy eye is hista-
mine. Together, this suggests that modulation of glutamatergic
signaling inthe SCA3trQ78 ﬂy wouldhave no effect. Wethere-
fore focused on the ASICs. Intriguingly, knockdown of one
ASICgeneintheﬂyeye,Nach,suppressedtheeyedegeneration
ofSCA3trQ78(Fig.5AandB),whereasknockdownofasecond
ASIC,pickpocket(ppk),onlypartiallysuppressedtheretinalde-
generation (Supplementary Material, Fig. S5). There are 16 dif-
ferent ASIC genes in the ﬂy genome. We tested all RNAi lines
available to these genes (14 genes) but did not see suppression
upon reduction in any additional genes (data not shown). It
could be that the reduction in a combination of two or more
oftheseotherASICproteinsmayberequiredtoofferprotection
intheSCA3 model, orthat Nachisthe primaryASIC mediating
the suppression of SCA3trQ78 in the retina.
SCA3 shares common pathogenic pathways to SCA1
Several lines of evidence suggest that ataxia proteins share
common molecular pathways. For example, in ﬂies reduction
in dAtx2 suppresses SCA3- and SCA1-induced pathogenesis
and up-regulation of the normal Ataxin-3 protein can suppress
Atx1Q82 (SCA1) degenerative phenotypes (12,13,44). We
Figure 4. Reduction in PICK1 expression in the SCA3trQ78 eye leads to less insoluble SCA3 protein. (A) Western blot detecting SCA3trQ78 with anti-HA
shows that reduction in PICK1 expression decreases the amount of insoluble SCA3trQ78 protein, present in the stacking gel, and increases the amount of
soluble SCA3trQ78 protein. Genotype w; rh1-GAL4, UAS-SCA3trQ78 in trans to indicated alleles. (B) Quantiﬁcation of the mean+SEM of six independent
repeats showing the ratio of soluble protein relative to the control strain (normalized to tubulin). One-way ANOVA followed by a Tukey’s test, ∗P , 0.05.
(C and D) Horizontal cryosections of ﬂies at d3 stained with anti-HA to detect SCA3trQ78. (C) Control ﬂies showing the accumulation of insoluble
SCA3trQ78. Genotype w; UAS-mCD8-GFP /+; gmr-GAL4, UAS-SCA3trQ78+. (D) Flies with reduced PICK1 expression show a slight reduction in the accu-
mulation of the SCA3trQ78 protein. Genotype w; gmr-GAL4, UAS-SCA3trQ78/UAS-PICK1-IR (E) SCA3trQ78 inclusions were quantiﬁed in cryosections from
animals expressing SCA3trQ78 compared with those expressing the disease protein but now with reduced PICK1 levels, mean+SEM. (F) Flies expressing
hTau.R406W in the eye show a degenerate, reduced eye. Reduction in PICK1 suppresses the small eye. The PICK1 deletion line delEP147 did not suppress the
small eye phenotype as robustly as the RNAi line, although the RNAi line reduces PICK1 expression to a much greater effect than the deletion. Genotype: w,
gmr-GAL4; UAS-htau.R406W in trans to indicated alleles. Double-headed arrow indicates length of ﬂy eye.
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thenormalAtx-1geneandSCA3.Todothis,wedown-regulated
DrosophilaAtx-1intheSCA3trQ78ﬂy.Thisrevealedadramat-
ic suppression of retinal degeneration (Fig. 6A and B), further
suggesting that SCA1 and SCA3 may share pathogenic path-
ways.Wethereforewentontotesttheeffectofdown-regulating
PICK1 in the SCA1 ﬂy model. Similar to expression of patho-
genic SCA3, expression of the Ataxin-1 protein bearing 82
polyglutamine repeats (hAtx1Q82) causes degeneration of the
external and internal retina (Fig. 6C) (41). This degeneration
was strongly suppressed by reduction in PICK1 (Fig. 6D);
however, in this situation, reduction in Nach did not suppress
hAtx1Q82-associated degeneration (data not shown). Thus,
degeneration by both pathogenic hAtx1 and SCA3 is mitigated
by PICK1 reduction, although ASIC proteins appear distinct as
Nach-mitigated SCA3 pathogenicity, whereas it had no effect
on SCA1 toxicity.
DISCUSSION
The polyQ diseases share several pathogenic cellular mechan-
isms, all of which result in neuronal toxicity and neuronal
degeneration. Ataxia occurs in several of the polyQ diseases,
such as the spinocerebellar ataxias, due to the neuronal loss
in the cerebellum and other motor control regions. A human
protein–protein interaction network of ataxia-associated
proteins revealed an interconnected network, suggesting that
the ataxia-causing genes, which share phenotypic features,
also share common molecular pathways (14). Using an
RNAi approach, we disrupted some of the major molecular
players proposed to be involved in interactions with
Ataxin-3 or this polyQ protein network: mitochondrial
dysfunction, cytoskeletal transport, genome stability or
calcium homeostasis (9). Our studies support the idea that
mitochondrial dysfunction and calcium homeostasis may be
critical. Moreover, although this network is based on the
normal proteins, and not the mutant proteins, our data
suggest the network can modulate pathogenicity of the pro-
teins associated with human disease in vivo.
Disrupting mitochondrial function by reducing the expres-
sion of three distinct mitochondrial genes, fh, Acon and
CG3731, enhanced SCA3 pathogenesis. These genes,
however, do not appear to be rate-limiting because
up-regulation of fh and Acon did not suppress degeneration.
Thus, neurons expressing pathogenic SCA3 are susceptible
to oxidative stress; however, up-regulation of components of
the frataxin network with drugs such as erythropoietin may
not be of beneﬁt to SCA3 patients as the processes inﬂuenced
by these genes is not dose-sensitive and rate-limiting in an
up-regulation manner. The key nodes of these networks that
are dose-sensitive would be important to reveal and target.
Two of the six proteins predicted to interact with the
Ataxin-3 protein also genetically modiﬁed SCA3 disease
pathogenesis in the ﬂy. Reduction in the gene encoding
cdc42 GTPase activating protein, RhoGAP68F, enhanced
pathogenesis, whereas loss of PICK1 suppressed toxicity, indi-
cating that reduction in PICK1 gene expression is neuroprotec-
tive. Recently, a small molecule inhibitor targeted to the PDZ
(post synaptic density protein-95, Drosophila disc large tumor
suppressor, and zonula occludens-1 protein) domain of PICK1
was identiﬁed (45,46). It is therefore plausible to test the effect
of inhibiting PICK1 function with small molecule inhibitors in
the treatment of SCA3 and in other SCA3 model systems (39).
PICK1 is known to transport subunits of ion channels to and
from the plasma membrane (30–33). The reduction in mam-
malian PICK1 function reduces excitotoxicity which has led
to great interest into therapeutically targeting PICK1 for ische-
mia (36). The mutant Ataxin-3 protein has also been found to
associate and activate calcium release from the calcium trans-
porter InsP3R1 (39). With this in mind, we investigated
whether other proteins involved in calcium homeostasis
could suppress SCA3 toxicity. This approach revealed that
reduction in Nach, an ASIC, recapitulated the suppression
observed with the reduction in PICK1, suggesting that this
channel may be involved in the toxicity of the pathogenic
SCA3 protein.
Our work also revealed that a reduction in the expression of
the Drosophila homologue of ATXN1, Atx-1, in the SCA3 ﬂy
model mitigated disease pathogenesis, suggesting that SCA1
and SCA3 pathogenesis may share more molecular pathways
than previously appreciated. These studies indicate that thera-
peutics directed at SCA1 may be of beneﬁt to SCA3 due to
overlapping functional pathways. We also tested whether
PICK1 reduction could mitigate hAtx1Q82 toxicity. This
result was unanticipated, as PICK1 had not been predicted
to bind to the Ataxin-1 protein in the ataxia interactome
Figure 5. Reduction in Nach, an ASIC, mitigates SCA3 pathogenesis. (A)
Control strain showing degeneration of the external eye and of the retina.
Genotype: w; gmr-GAL4, UAS-SCA3trQ78/UAS-mCD8-GFP. Double-headed
arrow indicates retinal tissue width. (B) Co-expression of an RNAi transgene
to Nach, an ASIC, suppresses the external internal degeneration induced by
SCA3trQ78. Genotype: w; gmr-GAL4, UAS-SCA3trQ78/UAS-Nach-IR.
Double-headed arrow indicates retinal tissue width.
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teins share molecular and pathogenic activities, since Dros-
ophila dAtx-2 interacts genetically with both hAtx-Q82 and
SCA3 (12,13). Given that we have found that reduction in
PICK1 can suppress both SCA3 and hAtx1-Q82 pathogenesis
in ﬂies, PICK1 may be involved in the shared pathogenic path-
ways.
Our data suggest that protein interaction networks may be
rich sources of genomic modiﬁcation pathways for pathogenic
proteins, and vice versa—such modiﬁers may be key candi-
dates to test for direct interactions with pathogenic proteins
of interest. Finally, our studies suggest that excitotoxic path-
ways may be of interest to attack not only in ischemic situa-
tions, but also in neurodegenerative situations.
MATERIALS AND METHODS
Drosophila stocks and crosses
Fly lines were grown in standard cornmeal molasses agar with
dry yeast at 258C. Transgenic lines for SCA3trQ78 have been
described previously (44,47,48). We used UAS-mCD8-GFP
as a control transgene to co-express a second transgenic line,
when comparing any experimental UAS-transgenic lines to
the normal degeneration induced by the SCA3 toxic protein.
RNAi lines included: PICK1 [P(KK109273)VIE-260B],
RhoGAP68F [P(KK102738)VIE-260B], Rad23 [P(KK1078
26)VIE-260B], Ice [w1118; P(GD12284)v28065 and w1118;
P(GD12284)v28064/TM3], CG7083 [P(KK101270)VIE-2
60B], CG3731 [P(KK108539)VIE-260B], Acon [P(KK100
999)VIE-260B] and Actn [w
1118; P(GD1354)v7760 and
w
1118; P(GD1354)v7762] from the VDRC stock center (49).
RNAi lines were also obtained to PICK1 (line TRiP.JF01199),
Atx-1 (line TRiP.HM05022), Nach (line TRiP.JF02566) and
ppk (line TRiP.JF03250) from TRiP at the Harvard Medical
School. The RNAi lines directed to frataxin homolog (fh)
have been described (50). All deﬁciency strains were obtained
from the Bloomington stock center, as was UAS-PKCi (51).
The PICK1 mutant ﬂies PICK1
delEP147 and PICK1
delEP197
(referred to here as delEP147 and delEP197) have been
described (26) and were a kind gift from Ole Kjaerulff (The
Panum Institute University of Copenhagen). The rh1-GAL4
driver was a gift of C. Desplan (New York University,
New York, USA) and UAS-htau.R406W a gift of M. Feany
(Harvard Medical School, Boston, MA, USA).
Histochemistry
Parafﬁn sections and cryosections were performed as
described (47,48). To examine the internal structure of the
retina 7 mm parafﬁn, sections were cut and mounted onto
glass slides. Tissue was visualized using the auto-ﬂuorescent
property of the ﬂy brain, and are presented in reverse black
and white images. For immunohistochemistry, primary anti-
bodies used were mouse anti-HA primary antibody
(5B1D10, 1:100, Invitrogen) and mouse anti-Myc (9E10,
1:100, Santa Cruz Biotechnology). Secondary antibodies
were anti-mouse conjugated to Alexa Fluor 594 or 488
(1:200 or 1:100, Molecular Probes). Western immunoblots
were performed as described (52). Protein was extracted in
Laemelli sample buffer (Bio-Rad) from 10 heads of each
Figure 6. SCA1 shares common pathogenic pathways to SCA3. (A) Control strain shows degeneration of the external eye and of the retina. Genotype: w;
gmr-GAL4, UAS-SCA3trQ78/UAS-mCD8-GFP. (B) Co-expression of an RNAi transgene directed to Atx-1 suppresses the SCA3 degeneration. w; gmr-GAL4,
UAS-SCA3trQ78/UAS-Atx-1-IR. (C and D) Reduction in PICK1 gene expression suppresses hAtx1Q82 degeneration. (C) Expression of the human Ataxin-1
protein with an expansion of Q82 causes degeneration of the external eye and of the retina. Genotype: w-; UAS-mCD8-GFP/+; gmr-GAL4 (YHIII),
UAS-hAtx1-Q82. (D) Co-expression of the RNAi transgene directed to PICK1 suppresses the SCA1-associated degeneration. Genotype: w-; gmr-GAL4,
UAS-Atx1 Q82/UAS-PICK1-IR. Double-headed arrow indicates retinal tissue width. (E) Global expression, with the da-GAL4 driver, of the RNAi transgene
directed to Atx-1 consistently reduces endogenous Atx-1 gene levels (mean+SEM, P , 0.03).
82 Human Molecular Genetics, 2012, Vol. 21, No. 1genotype, the protein was heat denatured and electrophoresed
under denaturing conditions. Each experiment was performed
six independent times. Antibodies used were anti-HA antibody
conjugated to horseradish peroxidase (3F10, 1:500, Roche),
mouse anti-tubulin (E7, 1:2,000, Developmental Studies
Hybridoma Bank) and goat anti-mouse IgG (1:2,500,
Jackson Laboratories). Signal was detected using
AmershamTM ECL Plus and chemiluminescence was detected
and quantiﬁed on the Fujiﬁlm LAS3000. One-way analysis of
variance (ANOVA) followed by a Tukey’s test was performed
to calculate statistically signiﬁcant changes in the ratio
between soluble SCA3trQ78 protein and tubulin loading
control.
Real-time PCR
To determine efﬁcient knockdown of PICK1, and Atx1 by
RNAi and for modulation of the SCA3trQ78 transgene, the
relative expression levels were determined by real-time
PCR. The trizol method was used to prepare RNA from 10
male ﬂies expressing the PICK1 RNAi transgene with the
daughterless (da)-GAL4 driver, 20 larvae expressing the
Atx-1 RNAi transgene with the da-GAL4 driver and from 10
heads co-expressing SCA3trQ78 with each of the suppressors
under the control of the rh1-GAL4 driver. Genomic DNA was
digested with turbo DNase from Ambion (AM1906). Invitro-
gen’s superscript II was used for ﬁrst strand synthesis with
random priming. For real-time analysis, Applied Biosystems
Fast SYBR
w Green Master Mix and Applied Biosystems
Power SYBR was used. Primers:
PICK1 FP2: 5′ AGCACCCATGTGTCCATGT 3′, PICK1
RP2: 5′ CTTGCCCTTCACGCTCAC 3′, b-tubulin FP: 5′
CATCCAAGCTGGTCAGTG 3′, b-tubulin RP: 5′ GCCA
TGCTCATCGGAGAT 3′, Atx-1 FP1: 5′ ATCCAATCGG
GAGGCAAC 3′, Atx-1 RP1: 5′ TCGTCGGAGAACCCATTG
3′, SCA3 FP1: 5′ CAGGACAGAGTTCACATCCATGT 3′,
SCA3 RP1: 5′ GCCTTACCTAGATCACTCCCAAGT 3′.
Each data set from each sample was normalized to
b-tubulin, and then each experimental data set was normalized
to the control data, all of which were performed using the
Applied Biosystems 7500 fast system software. Three tech-
nical replicates were performed on three independent
samples from each condition. Prism software was used to
perform one-way ANOVA followed by a Tukey’s test to cal-
culate statistical signiﬁcance.
Retinal pseudopupil analysis
Ommatidial counts were performed using pseudopupil pre-
parations as previously described (53). Photoreceptor
neurons were quantiﬁed by counting ommatidia in eyes of
female ﬂies d21 highlighted by optical neutralization. Heads
of ﬂies were mounted onto glass slides and visualized by a
light shining up through the head. Rhabdomeres were
counted in 10–20 ommatidia of n . 10 female ﬂies of each
genotype (100–200 minimum ommatidia/genotype). The
mean number of photoreceptors for each ommatidium was
plotted from three independent trials. Data are presented as
mean+SEM. The Kruskal–Wallis test was performed using
Prism software to calculate statistical signiﬁcance.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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